EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pharmacological properties and clinical trial results of datopotamab deruxtecan (Dato-DXd, Datroway®)

Takahiro Iijima, Daisuke Okajima

Folia Pharmacologica Japonica · 01.07.2026 · 161 (4) · 275-279

DOI: 10.1254/fpj.26028 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Folia Pharmacologica Japonica, erschienen am 01.07.2026. Verfasst von Takahiro Iijima und 1 weiteren Autor:innen. Beteiligte Einrichtung: Daiichi Sankyo Co., Ltd. Hauptthemen laut MEDLINE: Immunoconjugates, Antineoplastic Agents, Camptothecin, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugate (ADC) is a next-generation antibody therapeutics designed to deliver drugs selectively and efficiently to cancer cells, offering high efficacy and reduced side effects. Daiichi Sankyo has established a novel DXd-ADC technology using DXd, a derivative of the topoisomerase I inhibitor exatecan, as its payload. With this technology, we developed trastuzumab deruxtecan, the first DXd-ADC directed toward HER2. To generate a novel DXd-ADC covering unmet medical needs, we have developed a novel trophoblast cell surface antigen 2 (TROP2)-directed DXd-ADC, datopotamab deruxtecan (Dato-DXd). In the preclinical studies, we confirmed that Dato-DXd binds to TROP2 on cancer cell surface and, following internalization and lysosomal trafficking, releases DXd. The released DXd induces DNA damage and apoptosis in cancer cells. Additionally, Dato-DXd showed TROP2-dependent antitumor activity in multiple human cancer cell line-derived and patient-derived xenograft mouse models. Clinically, the global phase III trial targeting hormone receptor-positive, HER2-negative, unresectable or recurrent breast cancer led to its first approval in Japan in December 2024, followed by the approvals in the US and Europe later.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesAntineoplastic AgentsCamptothecinAntibodies, Monoclonal, HumanizedHumansAnimalsClinical Trials as TopicFemaleAntigens, Neoplasm

Substanzen

ImmunoconjugatesAntineoplastic AgentsCamptothecinAntibodies, Monoclonal, HumanizedAntigens, Neoplasm

Autor:innen und Institutionen

  • Daiichi Sankyo Co., Ltd.

Zitieren

APA

Iijima, T., & Okajima, D. (2026). Pharmacological properties and clinical trial results of datopotamab deruxtecan (Dato-DXd, Datroway®). Folia Pharmacologica Japonica, 161(4), 275-279. https://doi.org/10.1254/fpj.26028

Vancouver

Iijima T, Okajima D. Pharmacological properties and clinical trial results of datopotamab deruxtecan (Dato-DXd, Datroway®). Folia Pharmacologica Japonica. 2026;161(4):275-279. doi:10.1254/fpj.26028

BibTeX
@article{Iijima2026,
  author = {Iijima, Takahiro and Okajima, Daisuke},
  title = {Pharmacological properties and clinical trial results of datopotamab deruxtecan (Dato-DXd, Datroway®)},
  journal = {Folia Pharmacologica Japonica},
  year = {2026},
  volume = {161},
  number = {4},
  pages = {275--279},
  doi = {10.1254/fpj.26028}
}
Kostenlos starten →